Zelboraf (vemurafenib)

Zelboraf is an oral, small molecule, kinase inhibitor indicated for the treatment of patients with inoperable or metastatic melanoma with BRAF V600 mutations.
Zelboraf is not recommended for use in melanoma patients with wild-type BRAF.

Approved in the US, EU and Switzerland